LB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway

Figure 1 LB100 reduces body weight, ameliorates hepatic steatosis and attenuates liver injury in high fat diet-fed mice. A: Body weight and liver weight on the final day; B: Macroscopic view of livers from the four groups of mice; C: Representative liver histological section images of the four groups of mice stained with hematoxylin and eosin; D: Representative liver histological section images of the four groups of mice stained with oil red O; E: Triglyceride content of livers in the four groups; F: Serum levels of alanine aminotransferase and aspartate aminotransferase; G: Serum levels of insulin; H: Glucose tolerance test; I: Insulin tolerance test of mice fed with standard chow diet (SCD) or high fat diet (HFD) for 14 or 15 wk. Scale bar in panel represents 200 μm. Data are presented as the mean ± standard deviation. ^aP < 0.05, ^bP < 0.01 vs SCD mice; ^cP < 0.05, ^dP < 0.01 vs HFD mice. HFD: High fat diet; TG: Triglyceride; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GTT: Glucose tolerance test; ITT: Insulin tolerance test; SCD: Standard chow diet.